Rotator Cuff Tear Clinical Trial
Official title:
Pivotal, Non-Randomized, Historically Controlled, Prospective, Multi-Center Clinical Study of the Easytech Reversed Shoulder System
Verified date | September 2023 |
Source | FX Shoulder Solutions |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to collect data to demonstrate the safety and effectiveness of the Easytech Reversed Shoulder System for the treatment of patients who require a reverse total shoulder arthroplasty.
Status | Active, not recruiting |
Enrollment | 90 |
Est. completion date | December 28, 2024 |
Est. primary completion date | December 28, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: 1. Patients are 21 years or older. 2. Patients are skeletally mature as evident by scapula and proximal humerus closure. 3. Patients exhibit clinical indications for primary reverse total shoulder arthroplasty based on physical exam and medical history including the following: osteoarthritis, post-traumatic arthritis, or avascular necrosis. 4. Patients have a massive and non-repairable rotator cuff tear. 5. Patients have a functional deltoid muscle. 6. Patients are anatomically and structurally suited to receive the implants; a. Subject show sufficient bone quality in the humerus bone intraoperatively via the thumb test, guide pin test, humeral punch test, and humeral anchor test as outlined in the surgical technique. 7. Patients with an adjusted Constant Score < 60 and = 15. 8. Patients are willing and able to comply with the follow-up schedule and evaluation outlined in the protocol. 9. Patient are willing and able to sign the informed consent. Exclusion Criteria: 1. Patients with Body Mass Index (BMI) greater than 40 kg/m2. 2. Patients have one of the following compromising the affected limb: a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable. 3. Patients have marked bone loss that would not allow sufficient support of the implant. 4. Patients have a known sensitivity or allergic reaction to one or more of the implanted materials. 5. Patients who are participating concurrently in another clinical study, or have participated in a clinical study within the last 90 days, or intend to during the course of the study. 6. Patients who have an active systemic infection, or an active local infection in or near the target shoulder, or have a previous history of joint infection. 7. Patients with known immunodeficiency. 8. Patients currently taking > 5mg/day corticosteroids (e.g. prednisone) excluding inhalers, within 3 months prior to surgery. 9. Patients with significant comorbidities as evident by an American Society of Anesthesiologists (ASA) score greater than 3. 10. Patients with active neoplastic disease. 11. Patients with current drug or alcohol abuse, or a history of the same within the last 6 months. 12. Patients with local circulatory problems, (e.g. thrombophlebitis and lymphedema). 13. Patients are pregnant or expect to become pregnant during the duration of the study. 14. Patients with any mental or psychological disorder that would impair their ability to complete the study questionnaires. 15. Patients with any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the patient unable to perform appropriate postoperative rehabilitation. 16. Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance. 17. Patients with humeral or glenoid fractures. 18. Patients unable to stand from sitting position without the use of their hands/arms. 19. Patients with a history of fragility fractures as defined as any fall from a standing height or less, that results in a fracture. 20. Patients with osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease; a. Osteoporosis is defined as Simple Calculated Osteoporosis Risk Estimation (SCORE) above 6 and DXA (Dual-energy X-ray absorptiometry) T-score < -2.5 or QCT (Quantitative computed tomography) T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed. |
Country | Name | City | State |
---|---|---|---|
United States | Texas Orthopedic Specialists | Bedford | Texas |
United States | Carrell Clinic | Dallas | Texas |
United States | Dearborn & Associates Institute for Joint Reconstruction | Menlo Park | California |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | The CORE Institute | Sun City West | Arizona |
United States | Orthopedics Rhode Island | Wakefield | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
FX Shoulder Solutions |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adjusted Constant-Murley Score | adjusted Constant Score of 70 or greater, no humeral radiolucency >2mm or humeral migration/subsidence >5mm, no revision surgery, no serious device related adverse event | 24 months post-operative | |
Primary | no humeral radiolucency >2mm around the humeral component | on review of x-rays, there are no radiolucencies >2mm around the humeral component | 24 months post-operative | |
Primary | no subsidence or migration of the humeral component >5mm | on review of x-rays, there is no subsidence or migration of the humeral component greater than or equal to 5mm | 24 months post-operative | |
Primary | no revision | there is no revision of the humeral components | 24 months post-operative | |
Primary | no serious device related adverse event | there is no serious device related adverse event reported | 24 months post-operative | |
Secondary | QuickDASH | measures the ability to complete tasks, absorb forces and severity of symptoms | 24 months post-operative | |
Secondary | Visual Analog Scale for Pain (VAS) | on 100 point scale where 0 is no pain and 100 is severe pain | 24 months post-operative | |
Secondary | American Shoulder and Elbow Surgeon (ASES) | patient-reported outcomes with questions on function and pain | 24 months post-operative | |
Secondary | Range of Motion of the shoulder joint | forward and lateral elevation, internal & external rotation arm at side | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03663036 -
Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis
|
N/A | |
Suspended |
NCT03290196 -
The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics
|
Phase 4 | |
Active, not recruiting |
NCT03091075 -
Oxandrolone Rotator Cuff Trial
|
N/A | |
Completed |
NCT03380533 -
Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair
|
Phase 2/Phase 3 | |
Completed |
NCT04566939 -
A Long Term Follow-Up of Rotator Cuff Tear Patients Treated With Integrated Complementary and Alternative Medicine
|
||
Active, not recruiting |
NCT02716441 -
Rotator Cuff Failure With Continuity
|
||
Completed |
NCT03540030 -
Opioid-Free Shoulder Arthroplasty
|
Phase 4 | |
Completed |
NCT02298023 -
Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)
|
Phase 2 | |
Completed |
NCT01459536 -
Assessment of Muscle Function and Size in Older Adults With Rotator Cuff Tear
|
N/A | |
Completed |
NCT01383239 -
Impact of Postoperative Management on Outcomes and Healing of Rotator Cuff Repairs
|
N/A | |
Completed |
NCT02850211 -
A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair
|
Phase 4 | |
Completed |
NCT01204606 -
Arthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA)
|
N/A | |
Terminated |
NCT00936559 -
Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair
|
Phase 1 | |
Completed |
NCT01170312 -
Arthroscopic Surgery and Platelet Rich Plasma In Rotator Cuff Tear Evaluation
|
N/A | |
Completed |
NCT00852657 -
Comparison of Tendon Repair and Physiotherapy in the Treatment of Small and Medium-sized Tears of the Rotator Cuff
|
N/A | |
Active, not recruiting |
NCT00182299 -
An RCT to Compare the Outcomes of Patients With Large Rotator Cuff Repair That Undergo Repair With or Without SIS
|
Phase 4 | |
Recruiting |
NCT06120998 -
Quality of Life After Arthroscopic Rotator Cuff Repair
|
||
Completed |
NCT05897866 -
Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management (HSSM)
|
N/A | |
Completed |
NCT02644564 -
Early Clinical Examination and Ultrasonography Screening of Acute Soft Tissue Shoulder Injuries
|
N/A |